Search Results

Cell MedX Corp. (OTC Pink: CMXC) (“Cell MedX”, or the “Company”) a biotech company focusing on the discovery, development and commercialization of therapeutic

Cell MedX Corp. (OTC Pink: CMXC) (“Cell MedX”, or the “Company”) a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products

MedX Health Corp. is pleased to announce that, effective November 17, 2023, $2,965,000 of Secured Convertible Debentures were fully redeemed pursuant to exercise of the Conversion Rights by the Holders, resulting issuance of 59,300,000 common shares and 59,300,000 share purchase warrants exercisable at $0.20 until December 31, 2027.

Cell MedX Corp. (OTC Pink: CMXC) (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announces that Mr. Dwayne Yaretz

Cell MedX Corp. (“Cell MedX” or the “Company”) (OTC Pink: CMXC) announces that on November 22, 2023, the British Columbia Securities Commission

Cell MedX Corp. (OTC Pink: CMXC) (“Cell MedX” or the “Company”), a biotech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness,

MedX Health Corp. is pleased to announce that it is making an Application to the TSX-V for Acceptance of the proposed amendment to the terms of the currently outstanding Convertible Loan Notes.

MedX Health Corp. (“ MedX ” or the “ Company ”) (TSXV: MDX ) is pleased to announce that it is making an Application to the TSX Venture Exchange for Acceptance of the proposed amendment to the terms of 17,495,472 share purchase warrants (“ Warrants ”) issued in April, May, and July 2020 in connection with Private Placements completed at that time.